Abstract:, anidulafungin ( AFG ,and combinationsof FLC + AFG,AFG + AMB,andFLC + AMBagainst 17 C.albicans isolates obtained from the oral cavity of cancer patients. Isolates that had not been exposed to antifungals, served as a control group. Colony counts were performed at 0, 2, 4, 6, and 24 h after a brief ( 1 h ) antifungal exposure. Results: The FLC had no detectable post-antifungal effect independent of antifungal concentration and resembled drug-free FLC ( control ) . When all AMB and AFG were compared with FLC, significant variations in the post-antifungal effect were observed. Combining AFG and AMB with FLC resulted in effective activity compared to FLC alone. Combination regimens were rated as indifferent in general. Interestingly, low dosages of the AFG displayed increasing fungistatic action as it neared a fungistatic endpoint against C. albicans isolates ( n = 17 ) . Conclusion: Our findings suggest that brief exposure to AFG, in combination with FLC and AMB, at low concentrations of the medicines utilized, could be effective in the evaluation and optimization of new dosage regimens to manage candidiasis. However, future research will look at the clinical utility of our findings. albicans is the most common cause of nosocomial and are with morbidity and in However, limited therapeutic approaches against invasive candidiasis are available. The rise in antifungal resistance highlights the urgent need to develop new therapeutic options and novel this was an in regard of the showed a significant decrease in the number of loads,similar to the group with ATTAF-1 and ATTAF-2. Nevertheless, the results this study that the use of and ATTAF-2 as a therapeutic agent can exert significant in and in vivo antifungal effects C.albicans ,increasing animal and significantly decreasing loads. Conclusion: Although we have identified two new compounds, ATTAF-1 and ATTAF-2, as novel promising Candidates for the of studies of ATTAF-1 and ATTAF-2 activity and their action mechanisms in animal models are warranted to enhance our understanding and establish their efficacy. Antifungal-resistant dermatophytosis is an emerging threat with cases of chronic,recurrent infection reported from several countriesincluding India. Additionally, the rapidspread of infections involves person-to-personspread.Our results suggest that a clonal outbreak of a T. indotineae strain is circulating in multiple states in India. Current plans are to expand the geographic scope of the study by including over 10 countries from Europe, Middle East, and the Americas. This work will allow the publichealth community to better understandthe emergence and transmissionof antifungal-resistant dermatophytosis worldwide.

Candida albicans targets that potentially synergize with fluconazole

Combination of fluconazole with natural compounds: A promising strategy to manage resistant Candida albicans infections

Novel Potentially Antifungal Hybrids of 5-Flucytosine and Fluconazole: Design, Synthesis and Bioactive Evaluation.

Synergistic Effect of Fluconazole and Calcium Channel Blockers against Resistant Candida albicans

Small Molecule II-6s Synergises with Fluconazole Against Candida Albicans.

Synergistic in Vitro Activity of Sodium Houttuyfonate with Fluconazole Against Clinical Candida Albicans Strains under Planktonic Growing Conditions

Synergistic Antifungal Effect of Fluconazole Combined with Licofelone Against Resistant Candida Albicans

A mechanism study on the synergistic effects of rifapentine and fluconazole against fluconazole-resistant Candida albicans in vitro

Synergistic potential of teriflunomide with fluconazole against resistant Candida albicans in vitro and in vivo

Combining Fluconazole with Benzo[a]phenoxazine Derivatives as a Promising Strategy Against Fluconazole-Resistant Candida Species

The Combination of Minocycline and Fluconazole Causes Synergistic Growth Inhibition Against Candida Albicans: an in Vitro Interaction of Antifungal and Antibacterial Agents.

Synergic Effect of Deferoxamine Combined with Fluconazole Against Fluconazole-Resistant Candida Spp. Through Inhibited Cek1 MAPK Signaling Pathway

Synergistic Effect of the Combination of Deferoxamine and Fluconazole in Vitro and in Vivo Against Fluconazole-Resistant Candida Spp.

Fluphenazine Antagonizes with Fluconazole but Synergizes with Amphotericin B in the Treatment of Candidiasis

Synergistic Combinations of Antifungals and Anti-Virulence Agents to Fight Againstcandida Albicans

Potent in Vitro Synergism of Fluconazole and Berberine Chloride Against Clinical Isolates of Candida Albicans Resistant to Fluconazole

Synergistic Effect of Doxycycline and Fluconazole Against Candida Albicans Biofilms and the Impact of Calcium Channel Blockers.

Antifungal Effects of Phytocompounds on Candida Species Alone and in Combination with Fluconazole.

Novel aza-bicyclic 2-isoxazoline acylhydrazone hybrids and their synergistic potential with fluconazole against a drug-resistant Candida albicans strain

Antifungal Activity of Minocycline and Azoles Against Fluconazole-Resistant Candida Species

Synergistic effect of eravacycline combined with fluconazole against resistant Candida albicans in vitro and in vivo